Viral Hepatitis Prevention Board (VHPB)
Almost 3 decades active in the control and prevention of viral hepatitis in Europe
VHPB mission

Mission statement

The objective of VHPB is to contribute to the control and prevention of viral hepatitides:

- by drawing the attention to this important public health problem
- by issuing prevention and control guidance and catalyse the development of recommendations.
- by encouraging actions to improve control, prevention and elimination.

All activities are in line with viral hepatitis elimination goals defined by WHO Global strategy

Focus audiences are, in first instance, opinion leaders, policymakers, public health and health care professionals
1. Based on the available scientific evidence can treatment discontinuation for hepatitis B be considered
   - If yes: when and how?
   - If No: what is still needed to take an evidence based discussion

2. Treatment of Hepatitis B, will it be an influencing factor to reach the elimination goals set for hepatitis B should the targets be adapted (80% of diagnosed cases) when discontinuation of treatment will be considered
Activities: Two meetings a year

1. **Technical meeting:** discuss, review and issue guidelines or recommendations for critical issues in viral hepatitis

2. **Country meeting:**
   - Understand strategies and programs to control viral hepatitis in the country
   - Create awareness in the country for hepatitis as a public health problem
   - Create a platform where people of the country involved in viral hepatitis can discuss and can start future initiatives
   - Verify the WHO elimination targets and monitor the progress
   - Initiate or accelerate the development of National viral hepatitis plan
   - Draft guidelines to support countries based on lessons learned from other countries
VHPB advisors

- Antons Mozalevskis
  WHO-Euro
- Erika Duffell
  ECDC
- Marko Korenjak
  ELPA
- John Ward
  Global task force
- Maria Buti
  EASL
- Paige Armstrong
  CDC

- David Goldberg
  Scotland
- Mira Kojouharova
  Bulgaria
- Silvia Bino
  Albania
- Sema Mandal
  UK
VHPB advisors

Academic/University

- Paolo Bonanni
  Italy
- Vladimir Chulanov
  Russia
- Angela Domínguez
  Spain
- Karine Lacombe
  France
- Helène Norder
  Sweden
- Vana Papaevangelou
  Greece
- Mojca Maticic
  Slovenia
- Rui Tato Morinho
  Portugal
- Daniel Shouval
  Israel
- Pierre Van Damme
  Belgium
- Thomas Van Wollegem
  Belgium/The Netherlands
VHPB TECHNICAL MEETING

+++Online+++  

Long term hepatitis B vaccination and treatment

Meeting Agenda

29-30 March 2022

16h00 - 19h30 CEST
Meeting Objectives

• PART I – Vaccination
  o Long-term protection of hepatitis B vaccination
  o Provide information and data from recent and/or ongoing follow-up studies
  o Long-term impact of hepatitis B vaccination strategies including success stories
  o Discuss impact of growing vaccine hesitancy on long-term vaccination coverage
  o Discuss long term hepatitis B vaccination in relation to the WHO elimination goals

• PART II – Treatment
  o Discuss long-term outcomes of (new) hepatitis B treatment
  o Discuss treatment discontinuation
Meeting practical

• This is a very interactive meeting, questions and comments are welcome

• To facilitate the discussion
  – If you have question “raise your hand”
  – Switch on your camera
  – Chair will allow you to intervene
  – Unmute
  – Introduce yourself shortly